HIGH-LEVEL RESISTANCE TO (-) ENANTIOMERIC 2'-DEOXY-3'-THIACYTIDINE IN-VITRO IS DUE TO ONE AMINO-ACID SUBSTITUTION IN THE CATALYTIC SITE OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 REVERSE-TRANSCRIPTASE

被引:287
作者
BOUCHER, CAB
CAMMACK, N
SCHIPPER, P
SCHUURMAN, R
ROUSE, P
WAINBERG, MA
CAMERON, JM
机构
[1] UNIV AMSTERDAM,ACAD MED CTR,ANTIVIRAL THERAPY LAB,MEIBERGDREEF 15,1105 AZ AMSTERDAM,NETHERLANDS
[2] GLAXO GRP RES LTD,GREENFORD UB6 0HE,MIDDX,ENGLAND
[3] SIR MORTIMER B DAVIS JEWISH HOSP,LADY DAVIS INST,MONTREAL H3T 1E2,QUEBEC,CANADA
[4] MCGILL UNIV,CTR AIDS,MONTREAL H3T 1E2,PQ,CANADA
关键词
D O I
10.1128/AAC.37.10.2231
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Passage of human immunodeficiency virus type 1 in the presence of increasing 2'-deoxy-3'-thiacytidine (3TC) concentrations results in high-level (> 100-fold) 3TC-resistant viruses. All 3TC-resistant viruses possess a substitution at the second codon (from a methionine into an isoleucine) at position 184 within the highly conserved motif (YMDD) of human immunodeficiency virus type 1 reverse transcriptase. 3TC-resistant viruses were cross-resistant to the (-) enantiomer of the fluorinated derivative of BCH-189 but remained susceptible to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine. The susceptibilities of the 3TC-resistant viruses to the (+) enantiomers of BCH-189 and the fluorinated derivative of BCH-189 demonstrate an enantiomeric specificity for viruses selected under these conditions. Introduction of an isoleucine substitution at codon 184 into a background of two known 3'-azido-3'-deoxythymidine resistance mutations (amino acids 41 and 215) restored the susceptibility of this virus to 3'-azido-3'-deoxythymidine.
引用
收藏
页码:2231 / 2234
页数:4
相关论文
共 25 条
[1]  
ARGOS P, 1988, NUCLEIC ACIDS RES, V6, P3831
[2]   ORDERED APPEARANCE OF ZIDOVUDINE RESISTANCE MUTATIONS DURING TREATMENT OF 18 HUMAN IMMUNODEFICIENCY VIRUS-POSITIVE SUBJECTS [J].
BOUCHER, CAB ;
OSULLIVAN, E ;
MULDER, JW ;
RAMAUTARSING, C ;
KELLAM, P ;
DARBY, G ;
LANGE, JMA ;
GOUDSMIT, J ;
LARDER, BA .
JOURNAL OF INFECTIOUS DISEASES, 1992, 165 (01) :105-110
[3]  
BRODER S, 1990, AM J MED, V88
[4]   DEVELOPMENT OF A SENSITIVE QUANTITATIVE FOCAL ASSAY FOR HUMAN IMMUNODEFICIENCY VIRUS INFECTIVITY [J].
CHESEBRO, B ;
WEHRLY, K .
JOURNAL OF VIROLOGY, 1988, 62 (10) :3779-3788
[5]   (-)-2'-DEOXY-3'-THIACYTIDINE IS A POTENT, HIGHLY SELECTIVE INHIBITOR OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 AND TYPE-2 REPLICATION INVITRO [J].
COATES, JAV ;
CAMMACK, N ;
JENKINSON, HJ ;
JOWETT, AJ ;
JOWETT, MI ;
PEARSON, BA ;
PENN, CR ;
ROUSE, PL ;
VINER, KC ;
CAMERON, JM .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1992, 36 (04) :733-739
[6]   THE SEPARATED ENANTIOMERS OF 2'-DEOXY-3'-THIACYTIDINE (BCH-189) BOTH INHIBIT HUMAN-IMMUNODEFICIENCY-VIRUS REPLICATION INVITRO [J].
COATES, JAV ;
CAMMACK, N ;
JENKINSON, HJ ;
MUTTON, IM ;
PEARSON, BA ;
STORER, R ;
CAMERON, JM ;
PENN, CR .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1992, 36 (01) :202-205
[7]   THE SAME MUTATION THAT ENCODES LOW-LEVEL HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 RESISTANCE TO 2',3'-DIDEOXYINOSINE AND 2',3'-DIDEOXYCYTIDINE CONFERS HIGH-LEVEL RESISTANCE TO THE (-) ENANTIOMER OF 2',3'-DIDEOXY-3'-THIACYTIDINE [J].
GAO, Q ;
GU, ZX ;
PARNIAK, MA ;
CAMERON, J ;
CAMMACK, N ;
BOUCHER, C ;
WAINBERG, MA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1993, 37 (06) :1390-1392
[8]  
GAO Q, 1992, ANTIMICROB AGENTS CH, V37, P130
[9]   NOVEL MUTATION IN THE HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 REVERSE-TRANSCRIPTASE GENE THAT ENCODES CROSS-RESISTANCE TO 2',3'-DIDEOXYINOSINE AND 2',3'-DIDEOXYCYTIDINE [J].
GU, ZX ;
QING, G ;
LI, XG ;
PARNIAK, MA ;
WAINBERG, MA .
JOURNAL OF VIROLOGY, 1992, 66 (12) :7128-7135
[10]   INFECTION OF HTLV-III/LAV IN HTLV-I-CARRYING CELLS MT-2 AND MT-4 AND APPLICATION IN A PLAQUE-ASSAY [J].
HARADA, S ;
KOYANAGI, Y ;
YAMAMOTO, N .
SCIENCE, 1985, 229 (4713) :563-566